Castle Biosciences
Castle Biosciences Acquires Cernostics for up to $80M
Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.
Castle Biosciences Q2 Revenues Rise 79 Percent
The company said it delivered 70 percent more DecisionDx-Melanoma test results year over year, and that the total number of all tests delivered more than doubled.
May 11, 2021
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Nov 9, 2020
Castle Biosciences Q3 Revenues Up 3 Percent
Aug 10, 2020
Castle Biosciences Q2 Revenues Up 18 Percent
Jun 25, 2020
Castle Biosciences Prices $74M Public Offering
May 11, 2020